OptimizeRx (NASDAQ:OPRX) Earns Outperform Rating from William Blair

OptimizeRx (NASDAQ:OPRX)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Thursday,RTT News reports.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada lowered their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday. Barclays lowered their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday. JMP Securities lowered their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Thursday. Stifel Nicolaus lowered their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, B. Riley assumed coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.42.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $3.83 on Thursday. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $70.07 million, a PE ratio of -2.88 and a beta of 1.32. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a 50-day moving average price of $6.60 and a two-hundred day moving average price of $8.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Securities Group LLC bought a new stake in OptimizeRx in the second quarter valued at $25,000. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Quest Partners LLC boosted its holdings in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares in the last quarter. Connors Investor Services Inc. boosted its holdings in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Barclays PLC boosted its holdings in OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after acquiring an additional 21,060 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.